In a proof-of-concept clinical trial, the oral treatment candidate zanubrutinib was shown to reduce disease activity for 10 people with hard-to-treat immunoglobulin G4-related disease (IgG4-RD) affecting the tear and salivary glands. Importantly, according to the researchers, zanubrutinib showed disease-controlling potential as a standalone therapy, bypassing the need for…
Discussion
I’m all moved out of my old home. But fully settled into the new one? Not even close. Even with all the planning, the lists, the pacing, and the four full weeks I gave myself to move from one home to another, I still managed to overwhelm my body and…
Discussion
Valerio Therapeutics is teaming up with Abivax to discover new treatments for immune-mediated inflammatory diseases. The deal will provide funding to help advance Valerio’s internal pipeline, including a cell therapy candidate for IgG4‑related disease (IgG4‑RD), an immune-mediated inflammatory disease. “This collaboration brings together two highly complementary scientific…
Get regular updates to your inbox.
